283 related articles for article (PubMed ID: 32938533)
1. Assessment of Cardiotoxicity With Stem Cell-based Strategies.
Stella Stoter AM; Hirt MN; Stenzig J; Weinberger F
Clin Ther; 2020 Oct; 42(10):1892-1910. PubMed ID: 32938533
[TBL] [Abstract][Full Text] [Related]
2. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
Yang X; Papoian T
J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
[TBL] [Abstract][Full Text] [Related]
3. Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity.
Weng KC; Kurokawa YK; Hajek BS; Paladin JA; Shirure VS; George SC
Tissue Eng Part C Methods; 2020 Jan; 26(1):44-55. PubMed ID: 31797733
[TBL] [Abstract][Full Text] [Related]
4. Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity.
Sharma A; McKeithan WL; Serrano R; Kitani T; Burridge PW; Del Álamo JC; Mercola M; Wu JC
Nat Protoc; 2018 Dec; 13(12):3018-3041. PubMed ID: 30413796
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.
Zwartsen A; de Korte T; Nacken P; de Lange DW; Westerink RHS; Hondebrink L
J Mol Cell Cardiol; 2019 Nov; 136():102-112. PubMed ID: 31526813
[TBL] [Abstract][Full Text] [Related]
6. Human Heart Cardiomyocytes in Drug Discovery and Research: New Opportunities in Translational Sciences.
Abi-Gerges N; Miller PE; Ghetti A
Curr Pharm Biotechnol; 2020; 21(9):787-806. PubMed ID: 31820682
[TBL] [Abstract][Full Text] [Related]
7. Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems.
Magdy T; Schuldt AJT; Wu JC; Bernstein D; Burridge PW
Annu Rev Pharmacol Toxicol; 2018 Jan; 58():83-103. PubMed ID: 28992430
[TBL] [Abstract][Full Text] [Related]
8. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
[TBL] [Abstract][Full Text] [Related]
9. Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?
Sala L; Bellin M; Mummery CL
Br J Pharmacol; 2017 Nov; 174(21):3749-3765. PubMed ID: 27641943
[TBL] [Abstract][Full Text] [Related]
10. Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes.
Kopljar I; De Bondt A; Vinken P; Teisman A; Damiano B; Goeminne N; Van den Wyngaert I; Gallacher DJ; Lu HR
Br J Pharmacol; 2017 Nov; 174(21):3766-3779. PubMed ID: 28094846
[TBL] [Abstract][Full Text] [Related]
11. Population-based toxicity screening in human induced pluripotent stem cell-derived cardiomyocytes.
Burnett SD; Blanchette AD; Grimm FA; House JS; Reif DM; Wright FA; Chiu WA; Rusyn I
Toxicol Appl Pharmacol; 2019 Oct; 381():114711. PubMed ID: 31425687
[TBL] [Abstract][Full Text] [Related]
12. Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an in vitro model in toxicology: strengths and weaknesses for hazard identification and risk characterization.
Burnett SD; Blanchette AD; Chiu WA; Rusyn I
Expert Opin Drug Metab Toxicol; 2021 Aug; 17(8):887-902. PubMed ID: 33612039
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Cardiac Safety Assessment using hiPS-cardiomyocytes (Consortium for Safety Assessment using Human iPS Cells: CSAHi).
Takasuna K; Kazusa K; Hayakawa T
Curr Pharm Biotechnol; 2020; 21(9):829-841. PubMed ID: 31749424
[TBL] [Abstract][Full Text] [Related]
14. Stem cells for drug screening.
Laposa RR
J Cardiovasc Pharmacol; 2011 Sep; 58(3):240-5. PubMed ID: 21499120
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of in vitro models of stem cell-derived cardiomyocytes to screen for potential cardiotoxicity of chemicals.
Shi M; Tien NT; de Haan L; Louisse J; Rietjens IMCM; Bouwmeester H
Toxicol In Vitro; 2020 Sep; 67():104891. PubMed ID: 32446838
[TBL] [Abstract][Full Text] [Related]
16. Arrhythmia Mechanisms in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Paci M; Penttinen K; Pekkanen-Mattila M; Koivumäki JT
J Cardiovasc Pharmacol; 2020 Dec; 77(3):300-316. PubMed ID: 33323698
[TBL] [Abstract][Full Text] [Related]
17. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications.
Goldfracht I; Efraim Y; Shinnawi R; Kovalev E; Huber I; Gepstein A; Arbel G; Shaheen N; Tiburcy M; Zimmermann WH; Machluf M; Gepstein L
Acta Biomater; 2019 Jul; 92():145-159. PubMed ID: 31075518
[TBL] [Abstract][Full Text] [Related]
18. Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes.
Chaudhari U; Nemade H; Sureshkumar P; Vinken M; Ates G; Rogiers V; Hescheler J; Hengstler JG; Sachinidis A
Arch Toxicol; 2018 Jan; 92(1):371-381. PubMed ID: 28940058
[TBL] [Abstract][Full Text] [Related]
19. The Use of Voltage Sensitive Dye di-4-ANEPPS and Video-Based Contractility Measurements to Assess Drug Effects on Excitation-Contraction Coupling in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Hortigon-Vinagre MP; Zamora V; Burton FL; Smith GL
J Cardiovasc Pharmacol; 2021 Mar; 77(3):280-290. PubMed ID: 33109927
[TBL] [Abstract][Full Text] [Related]
20. Evolution of strategies to improve preclinical cardiac safety testing.
Gintant G; Sager PT; Stockbridge N
Nat Rev Drug Discov; 2016 Jul; 15(7):457-71. PubMed ID: 26893184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
